Kiniksa Pharmaceuticals, Ltd. provided earnings guidance for the full-year 2022. The company expects ARCALYST net revenue for the full-year 2022 to be between $115 million and $130 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
19.06 USD | +0.08% | -0.88% | +9.46% |
05-14 | Transcript : Kiniksa Pharmaceuticals, Ltd. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:40 AM | |
04-23 | Kiniksa Pharmaceuticals Q1 Loss Widens, Revenue Rises | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+9.46% | 1.35B | |
+9.95% | 118B | |
+10.90% | 106B | |
-8.71% | 23.4B | |
-1.63% | 22.1B | |
-9.77% | 18.34B | |
-41.70% | 16.59B | |
-15.64% | 15.97B | |
+6.48% | 14.03B | |
+20.67% | 11.67B |
- Stock Market
- Equities
- KNSA Stock
- News Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals, Ltd. Provides Earnings Guidance for the Full-Year 2022